ARTICLE SUMMARY:
With clinical outcomes for automated insulin delivery systems reaching parity, market success now hinges on overall user experience, and both ease of use and access will have major roles to play as new pump systems hit the market.
The US insulin pump market is experiencing double-digit growth, driven in large part by the success of automated insulin delivery (AID) systems, which combine an insulin pump with a continuous glucose monitoring (CGM) device and an automated dosing algorithm. AIDs have racked up a wealth of clinical data showing they can improve glucose control and help reduce the risk of dangerous hypoglycemic episodes. But with competitive AIDs reaching parity in terms of clinical outcomes, market success now hinges largely on the user experience. People are looking for technologies that can help ease the burden of diabetes care, and they are rewarding companies with simpler, smarter, and less costly solutions.
